Introduction
Chorioamnionitis is an acute inflammation of the fetal membranes, namely the chorion and amnion, accompanied by intrauterine infection. The International Classification of Diseases, Tenth Revision (ICD‑10) designates this condition as A60. The diagnosis is primarily clinical, supported by laboratory and histopathological findings. The infection can be polymicrobial or monomicrobial, with bacteria originating from the lower genital tract ascending into the amniotic cavity. The term A60 encompasses a spectrum of presentations ranging from asymptomatic colonization to fulminant infection with systemic involvement of the mother and fetus.
In obstetrics, the significance of chorioamnionitis is multifactorial. It represents a major obstetric complication, a key cause of preterm birth, and a risk factor for neonatal sepsis, cerebral palsy, and long‑term neurodevelopmental sequelae. Maternal morbidity includes uterine tenderness, fever, and, in severe cases, septicemia. Neonatal outcomes depend on gestational age, the extent of infection, and the timeliness of interventions. A comprehensive understanding of the pathophysiology, clinical features, and management protocols is essential for clinicians, midwives, and public health professionals.
Classification and Nomenclature
ICD‑10 Coding
The ICD‑10 system, maintained by the World Health Organization, assigns the code A60 to “Infection of the genital tract in pregnancy, childbirth and the puerperium.” Within this broad category, sub‑codes A60.0 through A60.9 describe specific pathogens and clinical scenarios. A60.0 is for “Chorioamnionitis, unspecified,” while A60.1–A60.9 denote infections caused by particular organisms, such as Neisseria gonorrhoeae (A60.1), Chlamydia trachomatis (A60.2), and other specified bacteria (A60.9). The classification facilitates epidemiological surveillance, reimbursement procedures, and research stratification.
Clinical Definitions
Clinical criteria for diagnosing chorioamnionitis vary among guidelines. A commonly accepted set of criteria includes maternal fever (≥38.0 °C), uterine tenderness, foul‑smelling amniotic fluid, and fetal tachycardia. The presence of two or more of these findings, in the absence of an alternative source of infection, typically prompts a provisional diagnosis. Histopathological confirmation - marked by neutrophilic infiltration of the chorionic plate, villi, and amniotic membrane - is considered the gold standard but is rarely performed in real‑time clinical settings.
Sub‑Classifications
Modern obstetric literature often subdivides chorioamnionitis into early‑onset and late‑onset forms. Early‑onset chorioamnionitis manifests before 34 weeks of gestation and is frequently associated with preterm premature rupture of membranes (PPROM). Late‑onset forms, occurring after 34 weeks, are more commonly linked to prolonged labor or invasive procedures such as epidural anesthesia. These distinctions influence management decisions and prognostication.
Epidemiology
Incidence
Reported incidence rates of A60 range from 2 % to 5 % of all pregnancies worldwide, depending on diagnostic criteria and surveillance methods. In low‑income countries, the rate may exceed 10 % due to limited access to prenatal care and higher prevalence of sexually transmitted infections. High‑income settings report rates around 2–3 %, reflecting better screening and prophylactic strategies.
Risk Factors
Several maternal and obstetric factors increase the likelihood of chorioamnionitis:
- Premature rupture of membranes (especially before 34 weeks)
- Prolonged or obstructed labor
- Multiple vaginal examinations during labor
- Use of intra‑uterine devices (IUDs) or other foreign bodies
- Maternal infections such as bacterial vaginosis, urinary tract infection, or sexually transmitted disease
- Previous history of chorioamnionitis or preterm delivery
- Low socioeconomic status and inadequate prenatal care
Geographical Distribution
The prevalence of A60 is markedly influenced by regional public health measures. In areas with comprehensive antenatal screening for group B streptococcus and early detection of bacterial vaginosis, the incidence is significantly reduced. Conversely, regions with limited access to healthcare, high rates of untreated sexually transmitted infections, and cultural practices that delay presentation for care exhibit higher incidence figures.
Etiology and Pathogenesis
Microbial Flora
Chorioamnionitis is predominantly bacterial in origin. The ascending infection model posits that polymicrobial flora from the vaginal canal invade the uterine cavity. Common bacterial groups include:
- Gram‑negative bacilli (e.g., Escherichia coli, Klebsiella spp.)
- Gram‑positive cocci (e.g., Streptococcus agalactiae, Staphylococcus aureus)
- Ureaplasma urealyticum and Mycoplasma hominis
- Viruses (e.g., cytomegalovirus, herpes simplex virus) are rarer but can cause intrauterine infection.
Immune Response
Once bacteria reach the amniotic cavity, the fetal membranes respond by recruiting neutrophils and other leukocytes, producing pro‑inflammatory cytokines such as interleukin‑6, interleukin‑8, and tumor necrosis factor‑α. These mediators contribute to uterine contraction, cervical ripening, and the eventual rupture of membranes. In severe cases, the inflammatory cascade propagates systemic maternal fever and can lead to septic shock.
Host Factors
Genetic predispositions affect the intensity of the inflammatory response. Polymorphisms in toll‑like receptor genes, cytokine genes, and other innate immunity components have been linked to increased susceptibility to chorioamnionitis. Maternal immune tolerance mechanisms are altered during pregnancy, potentially allowing bacterial colonization to progress unchecked.
Clinical Presentation
Maternal Signs
The classical maternal presentation includes a fever of 38 °C or higher, uterine tenderness, tachycardia, and a foul odor of amniotic fluid. In some cases, maternal chills, rigors, or hypotension may develop. Maternal laboratory markers such as an elevated white blood cell count and increased C‑reactive protein are supportive but not definitive.
Fetal Indicators
Fetal tachycardia, typically defined as a heart rate exceeding 160 beats per minute, is one of the earliest fetal manifestations. Absent fetal movements, variable decelerations on cardiotocography, and increased resistance indices in the umbilical artery may indicate fetal distress. In late‑onset disease, fetal signs may be subtle and require continuous monitoring.
Laboratory Findings
In the setting of chorioamnionitis, amniotic fluid cultures often yield the causative organisms. In addition, amniotic fluid white blood cell counts exceeding 200 cells/µL and the presence of polymorphonuclear neutrophils are indicative. Maternal blood cultures may be positive in severe cases, but a negative result does not exclude infection.
Diagnosis
Clinical Assessment
Initial diagnosis relies on the clinical presentation. The presence of maternal fever combined with at least one of the following: uterine tenderness, foul‑smelling amniotic fluid, or fetal tachycardia, is considered sufficient for a provisional diagnosis. However, false positives can occur due to non‑infectious causes of fever such as epidural anesthesia or uterine instrumentation.
Laboratory and Imaging Studies
Common laboratory tests include:
- Complete blood count (CBC) – leukocytosis with a left shift.
- C‑reactive protein (CRP) – elevated levels correlate with severity.
- Procalcitonin – may aid in distinguishing bacterial infection.
- Amniotic fluid analysis – white cell count, Gram stain, culture.
Ultrasound imaging may detect amniotic fluid echogenicity changes or placental abnormalities but is not diagnostic. Advanced modalities such as magnetic resonance imaging (MRI) are rarely employed in acute management.
Histopathology
Placental histology remains the definitive diagnostic method. Biopsy specimens from the placenta, chorion, and amnion are examined for neutrophilic infiltration and necrosis. The World Health Organization’s criteria for histological chorioamnionitis include neutrophil infiltration of the chorionic plate, villi, and decidua.
Management and Treatment
Antibiotic Therapy
Broad‑spectrum antibiotics are the cornerstone of treatment. The most widely accepted regimen includes:
- Intravenous ampicillin (or cloxacillin) 1.5 g every 6 hours.
- Gentamicin 5 mg/kg (maximum 200 mg) every 8 hours.
For suspected group B streptococcus (GBS) colonization, clindamycin or erythromycin may be used. In settings where methicillin‑resistant Staphylococcus aureus (MRSA) is prevalent, vancomycin is added. Antibiotic therapy should commence immediately upon diagnosis, irrespective of culture results, to mitigate the risk of maternal sepsis and neonatal infection.
Timing of Delivery
The decision to proceed with delivery depends on gestational age, fetal status, and maternal health. In early‑onset disease (before 34 weeks), the primary goal is to prolong pregnancy if possible, balancing the risks of infection progression against the benefits of fetal maturation. In late‑onset cases with confirmed fetal distress, an expedited delivery is often indicated. Cesarean section is typically performed for uncontrolled infection, severe maternal sepsis, or fetal compromise.
Supportive Care
Supportive measures include adequate hydration, monitoring of maternal vital signs, and, when necessary, vasopressors for hypotension. In cases of septic shock, early recognition and aggressive resuscitation following Advanced Life Support guidelines are vital.
Management and Treatment
Antibiotic Stewardship
Appropriate antibiotic selection requires knowledge of local resistance patterns. The use of third‑generation cephalosporins is common in many countries, but emerging resistance among gram‑negative organisms necessitates periodic review of empirical regimens. Antibiotic stewardship programs aim to reduce unnecessary antibiotic exposure while ensuring optimal coverage for A60.
Delivery Considerations
When labor is active, the continuation of vaginal examinations is often limited to avoid exacerbating infection. In many institutions, a single fetal heart rate measurement post‑diagnosis is performed, and continuous cardiotocography is instituted. If the gestational age is beyond viability (≥24 weeks), the obstetric team must decide between prolonging pregnancy with expectant management or proceeding with delivery, depending on maternal and fetal stability.
Neonatal Care
Newborns of mothers diagnosed with A60 require immediate evaluation for sepsis. Empirical antibiotic therapy often includes ampicillin plus gentamicin or cefotaxime. Early-onset sepsis protocols dictate initiation of antibiotics within the first hour of life, regardless of culture results, due to the high risk of morbidity and mortality. Sepsis work‑up includes CBC, blood cultures, lumbar puncture if indicated, and evaluation for intraventricular hemorrhage or meningitis via cranial ultrasound or MRI.
Post‑partum Follow‑up
Maternal follow‑up includes monitoring for persistent fever or signs of systemic infection. Serial CRP and procalcitonin measurements aid in determining the adequacy of antibiotic therapy. Neonatal neurodevelopmental assessments are conducted over the first year of life, especially in preterm infants, to detect early signs of cerebral palsy or developmental delay.
Prevention
Antenatal Screening
Routine prenatal visits provide an opportunity for screening and treatment of infections. Key preventive strategies include:
- Group B streptococcus screening at 35–37 weeks gestation and intrapartum prophylaxis with penicillin.
- Screening for bacterial vaginosis and urinary tract infections in the first trimester.
- Early detection and treatment of sexually transmitted infections such as Chlamydia trachomatis and Neisseria gonorrhoeae.
Patient Education
Educating expectant mothers on the signs of PPROM, the importance of timely presentation for care, and the risks associated with multiple vaginal examinations can reduce A60 incidence. Emphasis on hand hygiene and limiting unnecessary interventions during labor is crucial.
Intrapartum Measures
During labor, a single epidural catheter insertion and the use of sterile gloves for each vaginal examination are standard practices. In settings where intrapartum antibiotics are routinely administered following a fever of ≥38.0 °C, the incidence of neonatal sepsis due to A60 has decreased by up to 30 %. These measures underscore the importance of a multidisciplinary approach.
Prognosis
Maternal Outcomes
Maternal mortality directly attributable to A60 is rare in high‑income countries, with most deaths occurring in resource‑limited settings due to delayed treatment. In severe cases, septic shock can lead to multi‑organ failure and death. Long‑term sequelae include pelvic inflammatory disease and infertility, particularly when the infection is untreated or inadequately managed.
Neonatal Outcomes
Preterm infants, especially those delivered before 32 weeks, exhibit a higher risk of intraventricular hemorrhage, bronchopulmonary dysplasia, and retinopathy of prematurity. In term infants, early‑onset neonatal sepsis can manifest with temperature instability, feeding intolerance, and respiratory distress. Long‑term neurodevelopmental studies reveal increased rates of cerebral palsy and learning disabilities in children born to mothers with untreated A60.
Statistical Impact
Studies indicate that infants born after delivery complicated by chorioamnionitis have a two‑fold increased risk of neonatal sepsis compared to non‑infected controls. The risk of cerebral palsy is elevated by 1.5‑fold among infants delivered before 34 weeks due to infection‑related inflammation. These statistics emphasize the public health burden associated with A60 and justify preventive measures.
Complications
Maternal Complications
Severe maternal sepsis may evolve into septic shock, characterized by hypotension, tachycardia, and multi‑organ dysfunction. Invasive procedures such as hysterectomy are rarely required but can occur in refractory cases. Chronic pelvic pain and infertility may result from persistent inflammation or scarring of the uterine lining.
Neonatal Complications
Beyond sepsis, neonatal complications include:
- Respiratory distress syndrome (RDS) due to prematurity.
- Bronchopulmonary dysplasia (BPD) from prolonged mechanical ventilation.
- Intraventricular hemorrhage (IVH) – especially grades III–IV in preterm infants.
- Cerebral palsy – with an incidence increase of approximately 20 % in infants exposed to A60.
- Growth restriction and low birth weight.
Long‑Term Sequelae
Longitudinal studies reveal that children exposed to intrauterine infection are at higher risk of developmental delays, autism spectrum disorders, and attention‑deficit/hyperactivity disorder (ADHD). The mechanisms likely involve chronic inflammatory exposure and altered fetal neurodevelopment. Screening programs for early intervention are therefore recommended in high‑risk populations.
Research and Developments
Diagnostic Biomarkers
Recent research focuses on rapid bedside diagnostics such as point‑of‑care CRP and procalcitonin assays. Studies suggest that a procalcitonin threshold of >0.5 ng/mL, combined with clinical criteria, improves diagnostic accuracy and reduces unnecessary antibiotic use. Novel biomarkers, including matrix metalloproteinase‑8 (MMP‑8) and interleukin‑1β, are under investigation for their predictive value in early‑onset chorioamnionitis.
Therapeutic Innovations
There is growing interest in the use of adjunctive therapies such as anti‑inflammatory agents (e.g., dexamethasone) to attenuate fetal inflammatory responses. Trials involving intrapartum steroids have demonstrated reduced neonatal sepsis rates. Additionally, research into probiotics aims to restore healthy vaginal microbiota and prevent ascending infections.
Antibiotic Resistance
The rise of multi‑drug resistant organisms poses a significant challenge. Surveillance studies identify extended‑spectrum beta‑lactamase (ESBL) producing Enterobacteriaceae in a subset of A60 cases. Consequently, antibiotic stewardship programs are adapting empirical regimens to include carbapenems or third‑generation cephalosporins in high‑risk settings. Ongoing research seeks to refine local antibiograms to guide therapy more precisely.
Public Health Interventions
Global health initiatives emphasize the importance of preconception care and sexual health education to reduce A60. Interventions such as community‑based screening, mobile health clinics, and culturally tailored educational materials have shown promising reductions in PPROM and intra‑uterine infections in low‑resource countries.
Conclusion
Acute peripartum infection (A60) represents a complex interplay between maternal infection, fetal inflammation, and neonatal morbidity. Effective prevention hinges on robust antenatal screening, patient education, and intrapartum hygiene. Rapid antibiotic initiation remains the gold standard for treatment, with supportive measures and multidisciplinary coordination ensuring optimal outcomes. Emerging research into biomarkers and therapeutic adjuncts promises to refine both diagnosis and management, while antibiotic stewardship remains essential in the face of rising resistance.
No comments yet. Be the first to comment!